Magnetic dynamics studies of the newest-generation iron deficiency drugs based on ferumoxytol and iron isomaltoside 1000.

Magnetic dynamics studies by AC susceptibility technique have been performed on the two newest-generation iron deficiency drugs, commercialized under the trade names Feraheme and Monofer. In all aspects, these magnetic nanoparticle systems obey a common pattern of superparamagnetism characterized by similar blocking temperatures, average particle sizes, and magnetocrystalline anisotropy energy. However, effective magnetic moments associated with average particle of each drug are remarkably different, being approximately 10630 μB (Feraheme) and 134 μB (Monofer). The difference relies on qualitatively different magnetic interaction permeating the iron cores of the constituent nanoparticles. The nanoparticle of each system can be classified as monodomain ferrimagnet (Feraheme) and almost compensated antiferromagnet (Monofer). In accordance with different associated moments the dipole-dipole interaction between nanoparticles for the two drugs differs for orders of magnitudes but remains safely small at room temperatures. For reference, the corresponding measurements on previously better investigated iron-sucrose haematinic Venofer has been also performed and included in this article. [ABSTRACT FROM AUTHOR]